Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Publication
, Conference
Goudar, R; Keir, S; Hjelmeland, M; Conrad, C; Traxler, P; Lane, H; Wang, XF; Bigner, DD; Friedman, HS; Rich, JN
Published in: CLINICAL CANCER RESEARCH
December 1, 2003
Duke Scholars
Published In
CLINICAL CANCER RESEARCH
ISSN
1078-0432
Publication Date
December 1, 2003
Volume
9
Issue
16
Start / End Page
6090S / 6090S
Location
BOSTON, MASSACHUSETTS
Publisher
AMER ASSOC CANCER RESEARCH
Conference Name
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Goudar, R., Keir, S., Hjelmeland, M., Conrad, C., Traxler, P., Lane, H., … Rich, J. N. (2003). Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. In CLINICAL CANCER RESEARCH (Vol. 9, pp. 6090S-6090S). BOSTON, MASSACHUSETTS: AMER ASSOC CANCER RESEARCH.
Goudar, R., S. Keir, M. Hjelmeland, C. Conrad, P. Traxler, H. Lane, X. F. Wang, D. D. Bigner, H. S. Friedman, and J. N. Rich. “Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.” In CLINICAL CANCER RESEARCH, 9:6090S-6090S. AMER ASSOC CANCER RESEARCH, 2003.
Goudar R, Keir S, Hjelmeland M, Conrad C, Traxler P, Lane H, et al. Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. In: CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2003. p. 6090S-6090S.
Goudar, R., et al. “Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.” CLINICAL CANCER RESEARCH, vol. 9, no. 16, AMER ASSOC CANCER RESEARCH, 2003, pp. 6090S-6090S.
Goudar R, Keir S, Hjelmeland M, Conrad C, Traxler P, Lane H, Wang XF, Bigner DD, Friedman HS, Rich JN. Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2003. p. 6090S-6090S.
Published In
CLINICAL CANCER RESEARCH
ISSN
1078-0432
Publication Date
December 1, 2003
Volume
9
Issue
16
Start / End Page
6090S / 6090S
Location
BOSTON, MASSACHUSETTS
Publisher
AMER ASSOC CANCER RESEARCH
Conference Name
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis